Joanna Hellmuth1, James L K Fletcher2, Victor Valcour2, Eugène Kroon2, Jintanat Ananworanich2, Jintana Intasan2, Sukalaya Lerdlum2, Jared Narvid2, Mantana Pothisri2, Isabel Allen2, Shelly J Krebs2, Bonnie Slike2, Peeriya Prueksakaew2, Linda L Jagodzinski2, Suwanna Puttamaswin2, Nittaya Phanuphak2, Serena Spudich2. 1. From the Departments of Neurology (J.H., V.V.), Radiology (J.N.), and Epidemiology and Biostatistics (I.A.), University of California, San Francisco; SEARCH (J.L.K.F., E.K., J.I., P.P., S.P., N.P.), Thai Red Cross AIDS Research Centre, Bangkok, Thailand; US Military HIV Research Program (J.A., S.J.K., B.S., L.L.J.), Walter Reed Army Institute of Research, Silver Spring; Henry M. Jackson Foundation for the Advancement of Military Medicine (J.A., S.J.K., B.S.), Bethesda, MD; Department of Radiology (S.L., M.P.), Chulalongkorn University, Bangkok, Thailand; and Department of Neurology (S.S.), Yale University, New Haven, CT. joanna.hellmuth@ucsf.edu. 2. From the Departments of Neurology (J.H., V.V.), Radiology (J.N.), and Epidemiology and Biostatistics (I.A.), University of California, San Francisco; SEARCH (J.L.K.F., E.K., J.I., P.P., S.P., N.P.), Thai Red Cross AIDS Research Centre, Bangkok, Thailand; US Military HIV Research Program (J.A., S.J.K., B.S., L.L.J.), Walter Reed Army Institute of Research, Silver Spring; Henry M. Jackson Foundation for the Advancement of Military Medicine (J.A., S.J.K., B.S.), Bethesda, MD; Department of Radiology (S.L., M.P.), Chulalongkorn University, Bangkok, Thailand; and Department of Neurology (S.S.), Yale University, New Haven, CT.
Abstract
OBJECTIVE: To determine the incidence, timing, and severity of neurologic findings in acute HIV infection (pre-antibody seroconversion), as well as persistence with combination antiretroviral therapy (cART). METHODS: Participants identified with acute HIV were enrolled, underwent structured neurologic evaluations, immediately initiated cART, and were followed with neurologic evaluations at 4 and 12 weeks. Concurrent brain MRIs and both viral and inflammatory markers in plasma and CSF were obtained. RESULTS: Median estimated HIV infection duration was 19 days (range 3-56) at study entry for the 139 participants evaluated. Seventy-three participants (53%) experienced one or more neurologic findings in the 12 weeks after diagnosis, with one developing a fulminant neurologic manifestation (Guillain-Barré syndrome). A total of 245 neurologic findings were noted, reflecting cognitive symptoms (33%), motor findings (34%), and neuropathy (11%). Nearly half of the neurologic findings (n = 121, 49%) occurred at diagnosis, prior to cART initiation, and most of these (n = 110, 90%) remitted concurrent with 1 month on treatment. Only 9% of neurologic findings (n = 22) persisted at 24 weeks on cART. Nearly all neurologic findings (n = 236, 96%) were categorized as mild in severity. No structural neuroimaging abnormalities were observed. Participants with neurologic findings had a higher mean plasma log10 HIV RNA at diagnosis compared to those without neurologic findings (5.9 vs 5.4; p = 0.006). CONCLUSIONS: Acute HIV infection is commonly associated with mild neurologic findings that largely remit while on treatment, and may be mediated by direct viral factors. Severe neurologic manifestations are infrequent in treated acute HIV.
OBJECTIVE: To determine the incidence, timing, and severity of neurologic findings in acute HIV infection (pre-antibody seroconversion), as well as persistence with combination antiretroviral therapy (cART). METHODS: Participants identified with acute HIV were enrolled, underwent structured neurologic evaluations, immediately initiated cART, and were followed with neurologic evaluations at 4 and 12 weeks. Concurrent brain MRIs and both viral and inflammatory markers in plasma and CSF were obtained. RESULTS: Median estimated HIV infection duration was 19 days (range 3-56) at study entry for the 139 participants evaluated. Seventy-three participants (53%) experienced one or more neurologic findings in the 12 weeks after diagnosis, with one developing a fulminant neurologic manifestation (Guillain-Barré syndrome). A total of 245 neurologic findings were noted, reflecting cognitive symptoms (33%), motor findings (34%), and neuropathy (11%). Nearly half of the neurologic findings (n = 121, 49%) occurred at diagnosis, prior to cART initiation, and most of these (n = 110, 90%) remitted concurrent with 1 month on treatment. Only 9% of neurologic findings (n = 22) persisted at 24 weeks on cART. Nearly all neurologic findings (n = 236, 96%) were categorized as mild in severity. No structural neuroimaging abnormalities were observed. Participants with neurologic findings had a higher mean plasma log10 HIV RNA at diagnosis compared to those without neurologic findings (5.9 vs 5.4; p = 0.006). CONCLUSIONS: Acute HIV infection is commonly associated with mild neurologic findings that largely remit while on treatment, and may be mediated by direct viral factors. Severe neurologic manifestations are infrequent in treated acute HIV.
Authors: Dominique L Braun; Roger D Kouyos; Belinda Balmer; Christina Grube; Rainer Weber; Huldrych F Günthard Journal: Clin Infect Dis Date: 2015-05-19 Impact factor: 9.079
Authors: David J Moore; Scott L Letendre; Sheldon Morris; Anya Umlauf; Reena Deutsch; Davey M Smith; Susan Little; Alexandra Rooney; Donald R Franklin; Ben Gouaux; Shannon Leblanc; Debra Rosario; Christine Fennema-Notestine; Robert K Heaton; Ronald J Ellis; J Hampton Atkinson; Igor Grant Journal: J Neurovirol Date: 2010-12-15 Impact factor: 2.643
Authors: Lisa M Mangus; Rachel L Weinberg; Audrey C Knight; Suzanne E Queen; Robert J Adams; Joseph L Mankowski Journal: J Neuropathol Exp Neurol Date: 2019-01-01 Impact factor: 3.685
Authors: Edwina J Wright; Birgit Grund; Kevin R Robertson; Lucette Cysique; Bruce J Brew; Gary L Collins; Mollie Poehlman-Roediger; Michael J Vjecha; Augusto César Penalva de Oliveira; Barbara Standridge; Cate Carey; Anchalee Avihingsanon; Eric Florence; Jens D Lundgren; Alejandro Arenas-Pinto; Nicolas J Mueller; Alan Winston; Moses S Nsubuga; Luxshimi Lal; Richard W Price Journal: AIDS Date: 2018-05-15 Impact factor: 4.177
Authors: Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Alyssa C Vecchio; Christina M Marra; Jeffrey Schouten; Hongyu Jiang; Johnstone Kumwenda; Khuanchai Supparatpinyo; James Hakim; Ned Sacktor; Thomas B Campbell; Srikanth Tripathy; Nagalingeswaran Kumarasamy; Alberto La Rosa; Breno Santos; Marcus T Silva; Cecilia Kanyama; Cindy Firnhaber; Mina C Hosseinipour; Rosie Mngqibisa; Colin Hall; Paola Cinque; Kevin Robertson Journal: Clin Infect Dis Date: 2020-06-24 Impact factor: 9.079